SCHEMBL12009221

SCHEMBL12009221

O=C(OC(=O)c1ccc2c(c1)Cc1cc(C(=O)OC(=O)c3ccccc3)ccc1-2)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 3/20 0.60
▸ RAB9A P51151 3/20 0.53
▸ MAPT P10636 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ DRD2 P14416 1/20 0.48
▸ ADRA1D P25100 1/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ HTR2C P28335 1/20 0.48
▸ HTR7 P34969 1/20 0.48
▸ ADRA1A P35348 1/20 0.48
▸ ADRA1B P35368 1/20 0.48
▸ HTR2B P41595 1/20 0.48
▸ SRD5A1 P18405 2/20 0.47
▸ HSD17B1 P14061 1/20 0.46
▸ LMNA P02545 2/20 0.44
▸ F2 P00734 1/20 0.44
▸ CYP2C8 P10632 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13172184 0.92 RAB9A (0.68) SRD5A2RAB9AMAPTNPC1DRD2
SCHEMBL30738988 0.80 SRD5A2 (0.66) SRD5A2RAB9AMAPTNPC1DRD2
SCHEMBL2188139 0.80 SRD5A2 (0.66) SRD5A2RAB9AMAPTNPC1DRD2
SCHEMBL2186803 0.80 SRD5A2 (0.66) SRD5A2RAB9AMAPTNPC1DRD2
SCHEMBL8717537 0.79 LMNA (0.67) SRD5A2MAPTLMNAF2TSHR
SCHEMBL1115098 0.78 MAPT (0.63) SRD5A2RAB9AMAPTNPC1SRD5A1
SCHEMBL30935799 0.78 MAPT (0.63) SRD5A2RAB9AMAPTNPC1SRD5A1
SCHEMBL16731946 0.77 TTR (0.58) RAB9AMAPTNPC1HTR7HTR2B
SCHEMBL545343 0.77 LMNA (0.58) RAB9AMAPTLMNAF2TSHR
SCHEMBL4918684 0.77 SRD5A2 (0.66) SRD5A2RAB9AMAPTNPC1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220143201-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS (US) 2022-05-12 — — US disclosed
US-10695435-B2 Composition comprising a polymeric reagent NEKTAR THERAPEUTICS (US) 2020-06-30 — — US disclosed
US-20190046651-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS 2019-02-14 — — US disclosed
US-20170348426-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT NEKTAR THERAPEUTICS 2017-12-07 — — US disclosed
US-9381254-B2 Methods for preparing polymeric reagents NEKTAR THERAPEUTICS (US) 2016-07-05 — — US disclosed
US-20160022830-A1 METHODS FOR PREPARING POLYMERIC REAGENTS NEKTAR THERAPEUTICS 2016-01-28 — — US disclosed
US-9090740-B2 Methods for preparing polymeric reagents NEKTAR THERAPEUTICS (US) 2015-07-28 — — US disclosed
US-8911718-B2 Methods for preparing polymeric reagents NEKTAR THERAPEUTICS (US) 2014-12-16 — — US disclosed
US-8703115-B2 Methods for preparing conjugates NEKTAR THERAPEUTICS (US) 2014-04-22 — — US disclosed
US-20140107349-A1 Methods for Preparing Polymeric Reagents NEKTAR THERAPEUTICS (US) 2014-04-17 — — US disclosed
US-20130184443-A1 Methods for Preparing Conjugates NEKTAR THERAPEUTICS (US) 2013-07-18 — — US disclosed
US-8435505-B2 Pharmaceutical compositions and methods for delivering such compositions NEKTAR THERAPEUTICS (US) 2013-05-07 — — US disclosed
US-20120258912-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS NEKTAR THERAPEUTICS (US) 2012-10-11 — — US disclosed
US-8252275-B2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates NEKTAR THERAPEUTICS (US) 2012-08-28 — — US disclosed
US-8252275-B2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates NEKTAR THERAPEUTICS (US) 2012-08-28 — — US disclosed
EP-2279758-A2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates Nektar Therapeutics (US) 2011-02-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258912-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS ABCG2, SI, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SRD5A2 1923/4885RAB9A 2000/4885MAPT 339/4885
US-20220143201-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 SRD5A2 3458/4885RAB9A 3754/4885MAPT 1479/4885
US-20160022830-A1 METHODS FOR PREPARING POLYMERIC REAGENTS PAM, ALKBH3, DNPEP SRD5A2 4174/4885RAB9A 4002/4885MAPT 3976/4885
US-20130184443-A1 Methods for Preparing Conjugates SI, CD44, ABCG2 SRD5A2 2535/4885RAB9A 1640/4885MAPT 731/4885
US-20190046651-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 SRD5A2 3458/4885RAB9A 3754/4885MAPT 1479/4885
US-20170348426-A1 COMPOSITION COMPRISING A POLYMERIC REAGENT CD44, FCGRT, C9 SRD5A2 3458/4885RAB9A 3754/4885MAPT 1479/4885
US-10695435-B2 Composition comprising a polymeric reagent CD44, FCGRT, C9 SRD5A2 3458/4885RAB9A 3754/4885MAPT 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback